Table 1.
Patient characteristics and response to immunotherapy
| Patient | Age | Sex | Chemotherapy during vaccination | Number of vaccinations | DTH test for KLH positive after vaccination number | DTH test for tumor lysate positive after vaccination number | Percent increase over baseline in ELISPOT after vaccination | Stimulatory index before vaccination | Stimulatory index after vaccination | Best clinical response | Survival since diagnosis of advanced disease (mo) | Survival since first diagnosis of pancreatic cancer (mo) | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 40 | 58 | M | Gem | 9 | 3 | 6 | n.d. | 1.72 | 1.97 | PD | 11 | 85 | DOD |
| 42 | 62 | F | Gem | 6 | 2 | Never | n.d. | 1.05 | 1.78 | PD | 8 | 8 | DOD |
| 44 | 72 | F | Gem | 2 | n.d. | n.d. | n.d. | n.d. | n.d. | PD | 2 | 2 | DOD |
| 45 | 67 | M | Gem | 2 | n.d. | n.d. | n.d. | n.d. | n.d. | PD | 10 | 10 | DOD |
| 47 | 66 | F | Gem | 12 | 2 | 3 | 241 | 1.70 | 3.30 | SD | 38 | 39 | DOD |
| 51 | 58 | F | Gem | 8 | 6 | 6 | n.d. | 1.28 | 2.14 | PR | 7 | 14 | DOCa |
| 52 | 67 | M | GemOx | 11 | Never | Never | 354 | 6.49 | 8.48 | SD | 56 | 56 | DOD |
| 53 | 64 | F | GemOx | 8 | 7 | n.d. | n.d. | 1.68 | 3.67 | PD | 12 | 12 | DOD |
| 54 | 61 | M | Gem | 11 | 3 | n.d. | 153 | 1.86 | n.d. | PD | 51 | 51 | DOD |
| 56 | 61 | M | Gem | 4 | 1 | n.d. | n.d. | n.d. | n.d. | PD | 14 | 20 | DOD |
| 61 | 42 | M | Gem | 3 | n.d. | n.d. | n.d. | n.d. | n.d. | PD | 8 | 16 | DOD |
| 62 | 64 | M | Gem | 6 | 5 | 6 | n.d. | 1.43 | 1.91 | PD | 8 | 8 | DOD |
Gem gemcitabine mono, GemOx gemcitabine and oxaliplatin, PD progressive disease, SD stable disease, PR minor response, DOD dead of disease, DOC died of other causes
aPatient 51 succumbed to systemic deterioration without evidence of tumor progression